IN2014DN07194A - - Google Patents
Info
- Publication number
- IN2014DN07194A IN2014DN07194A IN7194DEN2014A IN2014DN07194A IN 2014DN07194 A IN2014DN07194 A IN 2014DN07194A IN 7194DEN2014 A IN7194DEN2014 A IN 7194DEN2014A IN 2014DN07194 A IN2014DN07194 A IN 2014DN07194A
- Authority
- IN
- India
- Prior art keywords
- bacteria
- resistant bacteria
- fulvic acid
- antibiotics
- drug resistant
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 abstract 5
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 abstract 2
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 229940088710 antibiotic agent Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940095100 fulvic acid Drugs 0.000 abstract 2
- 239000002509 fulvic acid Substances 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 abstract 1
- 108010040201 Polymyxins Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 108010068385 carbapenemase Proteins 0.000 abstract 1
- 229940041011 carbapenems Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201201683 | 2012-03-07 | ||
| PCT/IB2013/051772 WO2013132444A1 (en) | 2012-03-07 | 2013-03-06 | Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07194A true IN2014DN07194A (de) | 2015-04-24 |
Family
ID=48142838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7194DEN2014 IN2014DN07194A (de) | 2012-03-07 | 2013-03-06 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9265744B2 (de) |
| EP (1) | EP2822551B1 (de) |
| KR (1) | KR20140135813A (de) |
| CN (1) | CN104203227A (de) |
| IN (1) | IN2014DN07194A (de) |
| MY (1) | MY170829A (de) |
| RU (1) | RU2640928C2 (de) |
| WO (1) | WO2013132444A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| CN109706195B (zh) * | 2018-12-27 | 2022-04-08 | 齐齐哈尔龙江阜丰生物科技有限公司 | 颗粒型苏氨酸的生产工艺 |
| CN111616358A (zh) * | 2020-06-20 | 2020-09-04 | 田劭军 | 一种用于提高免疫力的组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225271A (en) | 1987-07-08 | 1991-02-26 | Nat Energy Council | Oxidising coal using a gaseous oxidant |
| DE3903773A1 (de) | 1988-02-11 | 1989-09-14 | Nat Energy Council | Eine mischung mit bakteriozider oder bakteriostatischer aktivitaet |
| US5204368A (en) | 1990-05-25 | 1993-04-20 | National Energy Council | Bacteriostatic and bacteriocidal method using fulvic acid derivatives |
| DE69939722D1 (de) | 1998-10-08 | 2008-11-20 | Pfeinsmith Ltd | Fulvinsäure und deren Verwendung in der Behandlung von Entzündungen |
| EP1895898B1 (de) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensoranordnung mit leitfähiger brücke |
| US8114910B2 (en) * | 2006-05-02 | 2012-02-14 | Pfeinsmith S.A. (Pty) Ltd. | Acidic composition |
| US8445452B2 (en) * | 2008-06-05 | 2013-05-21 | Pfeinsmith Ltd. | Fulvic acid and antibiotic combination |
-
2013
- 2013-03-06 IN IN7194DEN2014 patent/IN2014DN07194A/en unknown
- 2013-03-06 MY MYPI2014702359A patent/MY170829A/en unknown
- 2013-03-06 RU RU2014140227A patent/RU2640928C2/ru active
- 2013-03-06 CN CN201380012421.XA patent/CN104203227A/zh active Pending
- 2013-03-06 KR KR1020147028255A patent/KR20140135813A/ko not_active Application Discontinuation
- 2013-03-06 US US14/383,429 patent/US9265744B2/en active Active
- 2013-03-06 WO PCT/IB2013/051772 patent/WO2013132444A1/en active Application Filing
- 2013-03-06 EP EP13717565.9A patent/EP2822551B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140135813A (ko) | 2014-11-26 |
| US9265744B2 (en) | 2016-02-23 |
| US20150031767A1 (en) | 2015-01-29 |
| EP2822551A1 (de) | 2015-01-14 |
| RU2640928C2 (ru) | 2018-01-12 |
| WO2013132444A1 (en) | 2013-09-12 |
| RU2014140227A (ru) | 2016-04-27 |
| MY170829A (en) | 2019-09-05 |
| EP2822551B1 (de) | 2016-12-21 |
| CN104203227A (zh) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013184755A3 (en) | Seca inhibitors and methods of making and using thereof | |
| PH12016501512B1 (en) | Treatment for resistant acne | |
| MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
| MX2016002765A (es) | Empleo de una composicion que comprende microorganismos para aumentar la produccion intestinal de acido butirico, acido folico o niacina y/o disminuir la produccion intestinal de acido succinico. | |
| IN2015DN01198A (de) | ||
| MX2019012877A (es) | Prevencion, interrupcion y tratamiento de biopeliculas con lisina de bacteriofago. | |
| EP4233545A3 (de) | Synergistische bakterielle zusammensetzungen und verfahren zur herstellung und verwendung davon | |
| TN2013000310A1 (en) | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections | |
| WO2017017631A3 (en) | Antibacterial therapeutics and prophylactics | |
| WO2014007951A3 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX353705B (es) | Nanoparticulas de quitosana derivadas dualmente y metodos de fabricacion y uso de las mismas para transferencia genetica in vivo. | |
| MX352760B (es) | Metodos para tratar infecciones intrapulmonares. | |
| MX363678B (es) | Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas. | |
| SG10201900541QA (en) | Derivatives of xanthone compounds | |
| BR112014002940A2 (pt) | uso e composição agroquímica de dibutilamidas de ácido carboxílico | |
| IN2014DN07194A (de) | ||
| WO2013162772A3 (en) | Perforin 2 defense against invasive and multidrug resistant pathogens | |
| AU2012335397A8 (en) | Novel bacteriophages | |
| UA118554C2 (uk) | Синергетичні суміші антимікробних засобів, корисні для контролю мікроорганізмів у промислових процесах | |
| NZ713440A (en) | Nsaid administration and related compositions, methods and systems. | |
| MY180113A (en) | Use of patchouli extract in the preparation of compositions with an anti-microorganism effect | |
| IN2015DN02513A (de) | ||
| Opoku | AmpC Beta-Lactamase Production Among Pseudomonas Aeruginosa and proteus Mirabilis Clinical Isolates at the Komfo Anakye Teaching hospital in Kumasi, Ghana | |
| MX2016005869A (es) | Inhibidor de beta-lactamasa cristalina. | |
| RU2015133469A (ru) | Антимикробная комбинация в отношении устойчивых к карбапенемам грамотрицательных микроорганизмов, продуцирующих металло-β-лактамазу |